Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice. by Willemin, G. et al.
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2013, Article ID 972962, 12 pages
http://dx.doi.org/10.1155/2013/972962
Research Article
Major Histocompatibility Class II Pathway Is Not Required for
the Development of Nonalcoholic Fatty Liver Disease in Mice
Gilles Willemin,1 Catherine Roger,2 Armelle Bauduret,2 and Kaori Minehira1,3
1 Department of Physiology, University of Lausanne, Rue du Bugnon 7, 1005 Lausanne, Switzerland
2 Center for Integrative Genomics, University of Lausanne, 1010 Lausanne, Switzerland
3Nestle´ Research Center, Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland
Correspondence should be addressed to Kaori Minehira; kaori.minehira@unil.ch
Received 12 February 2013; Accepted 22 March 2013
Academic Editor: Jun Ding
Copyright © 2013 Gilles Willemin et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Single-nucleotide polymorphisms within major histocompatibility class II (MHC II) genes have been associated with an increased
risk of drug-induced liver injury. However, it has never been addressed whether theMHC II pathway plays an important role in the
development of nonalcoholic fatty liver disease, themost common form of liver disease.We used amousemodel that has a complete
knockdownof genes in theMHC II pathway (MHCIIΔ/Δ). Firstlywe studied the effect of high-fat diet-induced hepatic inflammation
in these mice. Secondly we studied the development of carbon-tetra-chloride- (CCl
4
-) induced hepatic cirrhosis. After the high-
fat diet, both groups developed obesity and hepatic steatosis with a similar degree of hepatic inflammation, suggesting no impact
of the knockdown of MHC II on high-fat diet-induced inflammation in mice. In the second study, we confirmed that the CCl
4
injection significantly upregulated the MHC II genes in wild-type mice. The CCl
4
treatment significantly induced genes related
to the fibrosis formation in wild-type mice, whereas this was lower in MHCIIΔ/Δ mice. The liver histology, however, showed no
detectable difference between groups, suggesting that the MHC II pathway is not required for the development of hepatic fibrosis
induced by CCl
4
.
1. Introduction
Major histocompatibility class II (MHC II) pathway plays
an important role in immune function. The molecules of
MHC II are expressed on the surface of antigen-presenting
cells such as macrophages, B cells, and dendritic cells [1].
Once the processed antigen loaded onto MHC II molecules
is presented on the surface of the cells, it promotes the
CD4+ helper T cell recognition. This results in an immune
response including the production of inflammatory cytokines
[2]. Although the importance of the pathway has been
widely studied in the immune processing, its specific roles
on hepatic inflammation and fibrosis have not been clearly
understood.
A genome-wide association study identified single-
nucleotide polymorphisms (SNPs) in theMHC II pathway in
lumiracoxib-treated patients that developed a liver injury [3].
The alleles of the genes (HLA-DRB1, 5, -DQB1, and -DQA1)
had a strong association with elevated plasma liver enzymes
in patients that developed the liver injury after the lumira-
coxib treatment. Lumiracoxib, a selective cyclooxygenase-2
(COX-2) inhibitor, has been used for osteoarthritis and acute
pain treatment [4, 5]. The use of this COX-2 inhibitor is
correlated with an increased risk of cardiovascular events and
an acute hepatotoxicity [6, 7]. However whether the MHC
II pathway has been involved in the mechanism of these
diseases has not been clarified.
A similar observation has been reported with a treatment
of amoxicillin-clavulanate, an antimicrobial agent [8, 9].
Again the SNPs in the region around HLA-DRB1 and HLA-
DQB1 showed a strong association with the drug-induced
liver injury. Interestingly, the alleles in HLA-DQB1 locus
were also strongly associated with primary biliary cirrhosis
[10], which is the most common autoimmune liver disease.
During the development of biliary cirrhosis, T lympho-
cytes play an important role [11, 12], and a link between
2 International Journal of Endocrinology
209 bp
173 bp
WT Het WT KO WT Blank STD
W
T 
PC
R
KO
 P
CR
W
T 
PC
R
KO
 P
CR
W
T 
PC
R
KO
 P
CR
W
T 
PC
R
KO
 P
CR
W
T 
PC
R
KO
 P
CR
W
T 
PC
R
KO
 P
CR
(a)
0
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
Fo
ld
 ch
an
ge
H2-Eb1 H2-Aa H2-Ab1
∗ ∗ ∗
WT
MHCIIΔ/Δ
(b)
Figure 1: MHCII gene genotyping and hepatic expression in wild-type and MHCIIΔ/Δ mice. (a) Two different PCRs were performed for the
detection of wild-type (WT PCR) and knockout (KO PCR:MHCIIΔ/Δ) fragments; 173 bp for aWT band and 209 bp for a KO band.Therefore
heterozygous (Het) presents both bands. (b) Gene expression ofMHC II genes (H2-Eb1, -Aa, -Ab1) in liver samples by real-time RT-PCR.The
expression was normalized by 𝛽2 microglobulin and compared to the wild-type. Open bars represent wild-type and closed bars MHCIIΔ/Δ
mice (𝑛 = 10–14/group). Data are presented as mean ± SEM. ∗Significantly different from wild-type mice, 𝑃 < 0.05 (Student t-test).
the T lymphocytes hyperactivity and drug-induced liver
injuries has been recently suggested [13]. In addition, several
studies have demonstrated that the genes in the MHC II
pathway were significantly upregulated in porcine-serum-
induced hepatic fibrosis in rats [14, 15]. These facts imply a
strong influence of the MHC II pathway on the susceptibility
to develop liver diseases.
Nonalcoholic fatty liver disease (NAFLD) is one of the
major liver diseases in industrialized countries. Data are
suggesting a strong increase of NAFLDprevalence in the next
decades [16, 17]. The disease consists of a diverse spectrum
of liver pathologies, starting by hepatic steatosis and then
steatohepatitis, a state of hepatic inflammation [18]. Then
it progresses toward hepatic fibrosis, cirrhosis, and hepatic
carcinoma. Although some molecular pathways that lead to
hepatitis in NAFLD can also be activated in the drug-induced
liver injuries, the implication ofMHCII pathway has not been
clearly understood in NAFLD model. Given the repeated
reports on the association between alleles on MHC II genes
and the susceptibility to a liver inflammation [3, 8–10], this
pathway might play an important role in the development of
NAFLD.
In the present study, we addressed whether the MHC II
pathway might be required for hepatitis development and
fibrosis formation. To this end, we chose to use a mouse
model lacking all conventional genes inMHC II pathway [19].
The entireMHC II region (80 kb) was deleted, resulting in the
removal of the genes encoding the MHC II pathway (H2-A𝛽,
-A𝛼, -E𝛽, -E𝛽2, and -E𝛼). The mouse genes H2-A𝛽 and -E𝛽
have the closest homology to the human HLA-DQB1 gene.
These mice are viable and fertile without major anatomical
or physiological abnormalities [19]. We have studied whether
these mice were protected against a high-fat diet-induced
hepatitis and a chemical-induced hepatic fibrosis.
2. Research Design and Method
2.1. Animals, Diet, and Chemicals. B6;129S2-𝐻2𝑑𝑙𝐴𝑏1-𝐸𝑎/J
(strain 003584, MHCIIΔ/Δ) mice in which the 80 kb of MHC
II region is deleted were purchased from Jackson Labora-
tories (Bar Harbor, ME, USA). These mice were bred with
C57B6/J mice and the F2 generation was crossbred to obtain
MHCIIΔ/Δ and wild-type mice. These mice were housed
in ventilated cages at an animal facility of the University
of Lausanne with 12-hour light and dark cycles and free
access to food and water. Five-week-old male mice were
subjected to high-fat diet (D12451, Research diets Inc., New
Brunswick, NJ, USA) for 4 months. The dietary composition
of the high-fat diet was carbohydrates 35%, fat 45%, and
protein 20%. Dietary protein was originated from casein,
and fat was mainly from lard. All animal procedures used
in this study were approved by the Swiss cantonal veterinary
service.
Carbon tetrachloride (CCl
4
), chloroform, methanol,
EDTA, sirius red, and aprotinin were purchased from Sigma-
Aldrich (Munich, Germany). Kits for measuring plasma
alanine transaminase (ALT), aspartate transaminase (AST),
and triglycerides (TG)were purchased fromWakoChemicals
(Neuss, Germany). Hematoxylin& eosinwas purchased from
Merck (Geneva, Switzerland).
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Figure 2: Effect of high-fat diet on metabolic parameters in wild-type and MHCIIΔ/Δ mice. Open circle/bars represent wild-type and closed
circle/bars MHCIIΔ/Δ mice (wild-type: 𝑛 = 25, MHCIIΔ/Δ: 𝑛 = 20). Data are presented as mean ± SEM. (a) Body weight gain during 4-month
diet. (b) Glucose tolerance test was performed around the 15th week of the intervention. (c) Liver weight at 16th week. (d) Fasting plasma
insulin concentration at 16th week. (e) Fasting blood glucose concentration at 16th week.
2.2. High-Fat Diet Experiment. Five-week-old male
MHCIIΔ/Δ mice and wild-type mice were assigned into
the high-fat diet described above. Body weight was measured
every month. A glucose tolerance test was performed around
the 15th week of the intervention. Mice were fasted for 4
hours and a solution of 1 g of glucose per kg of mouse was
injected intraperitoneally. Glycemia was monitored at 0, 15,
30, 60, and 120min using a glucometer (Bayer, Zurich, Switz-
erland).
At the end of the 4-month experiment, mice were fasted
for 4 hours and glycemia was measured by a glucometer.
Blood was collected by an intracardiac puncture and placed
into a tube containing EDTA and aprotinin (2mM and 0.1-
0.2 TIU, respectively) on ice. The plasma was then separated
4 International Journal of Endocrinology
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Figure 3: Effect of high-fat diet on liver enzymes, lipids, and inflammatory markers in wild-type and MHCIIΔ/Δ mice. Open bars represent
wild-type and closed bars MHCIIΔ/Δ mice (wild-type: 𝑛 = 25, MHCIIΔ/Δ: 𝑛 = 20). Data are presented as mean ± SEM. (a) Plasma ALT level
at 16th week. (b) Plasma AST level. (c) Liver triglyceride content at 16th week. (d) Fasting active plasma PAI-1 concentration at 16th week. (e)
Gene expression related to inflammation and fibrogenesis in the liver at 16th week.
by centrifugation and stored at−80∘Cuntil analysis. Liver and
epididymal adipose tissues were harvested and weighed. The
organs were flash-frozen into liquid nitrogen and stored at
−80∘C until analysis.
2.3. CCl
4
Treatment. To study the development of hepatic
fibrosis, 8-week-oldwild-type andMHCIIΔ/Δmalemicewere
treated by 1.25𝜇L/g body weight CCl
4
(25% in sunflower oil)
twice a week during 4 weeks. Another set of mice was treated
by sunflower oil as control vehicle at the same time. Twenty
hours following the last treatment, mice were fasted for 4
hours and anesthetized for a cardiac puncture. After sacrifice,
blood and liver were kept for further analysis. Fresh liver
pieces were put into 4% paraformaldehyde solution during
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Figure 4: Effect of high-fat diet on liver histology in wild-type and MHCIIΔ/Δ mice. (a) Oil red O staining (red color represents the lipid
accumulation). (b) Hematoxylin and eosin (H&E) staining. (c) F4/80 immunohistochemistry (macrophages were stained in brown: arrows).
4 hours. After several washings with PBS, liver samples were
dehydrated and parafinated for histological analysis.
2.4. Histology. Parafinated liver samples were sliced (4𝜇m)
and stained according to a standard technique with hema-
toxylin and eosin (H&E) using routine methods. To study
the fibrosis formation, 0.1% sirius red was used to stain
collagen I, III, and bile pigment using a protocol described
elsewhere [20]. For the histological samples, photos were
takenwith anAXIO ImagerM1with fluo-AxiocamMRmand
color Axiocam MRc cameras (Carl Zeiss AG, Oberkochen,
Germany). Images were treated by Axiovision release 4.8.2.
We then quantified the fibrotic area by assessing the ratio of
the red-stained area (fibrosis) to the total area, the vascular
luminal area being subtracted if present, using Photoshop
(Adobe Systems, Mountain View, USA) in five images per
section of the sample (10 x magnification).
Immunohistochemistry by glial fibrillary acidic protein
(GFAP) stain was performed by the subsequent incuba-
tions of the slices with rabbit anti-GFAP primary antibody
(Dako, Glostrup, Denmark) diluted in normal goat serum
for overnight at 4∘C, then with goat anti-rabbit coupled with
Alexa Fluor 568 (Life Technologies, Carlsbad, USA) for 30
minutes in the dark at room temperature. Immunostained
sections were then counterstained with 4󸀠,6-diamidino-2-
phenylindole (DAPI), embedded with mowiol and analyzed
using the Zeiss microscope.
2.5. Plasma Parameters and Liver Lipids Analysis. Total
plasma ALT and AST were measured by the Roche/Hitachi
6 International Journal of Endocrinology
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Figure 5: Effect of 4-week CCl
4
treatment on liver and blood glucose in wild-type and MHCIIΔ/Δ mice. Open bars represent oil-treated
wild-type (WT-oil), closed bars CCl
4
-treated wild-type (WT-CCl
4
), gray bars oil-treated MHCIIΔ/Δ mice, and semiclosed bars CCl
4
-treated
MHCIIΔ/Δ mice (wild-type oil: 𝑛 = 7, MHCIIΔ/Δ oil: 𝑛 = 5, wild-type CCl
4
: 𝑛 = 11, MHCIIΔ/Δ CCl
4
: 𝑛 = 9). Data are presented as mean
± SEM. (a) Liver weight. (b) Fasting blood glucose decreased after the CCl
4
treatment in both groups. (c), (d) Strong increase in fasting
plasma ALT and AST was observed after the CCl
4
treatment. a,b,c𝑃 < 0.05, ANOVA and Tukey Kramer HSD test. Different letters indicate
the significant difference between groups.
912 instrument with the commercial kits mentioned ear-
lier. Insulin was measured by a Mouse Insulin ELISA kit
(Mercodia, Uppsala, Sweden). Plasma active Plasminogen
activator inhibitor-1 (PAI-1) was also measured by an ELISA
kit (Molecular Innovations Inc., Novi).
From the harvested liver samples, total lipids were
extracted using a modified Folch method [21, 22]. For the
measurement of hepatic TG content, total lipid extract was
subjected to SPE columns (Interchim, Montluc¸on, France) to
separate TG [23, 24]. TGwere thenmixed with a chloroform-
triton X (1%) solution and dried under N
2
gas. TG were thus
dissolved into water and the content of TG was measured by
the use of the Wako Chemical kit.
2.6. Genotyping and Real-Time Polymerase Chain Reaction
(PCR). Ear DNA was extracted by the hotSHOT protocol
[25]. Genotyping was performed according to Jackson labo-
ratory’s protocol (http://jaxmice.jax.org/strain/003584.html).
Briefly, 2 sets of primers were used for the mutated
gene (oIMR1020: 5󸀠-Cgg AAg TgC TTg ACA TTg g-3󸀠,
oIMR1021:5󸀠-gTA TTg ACC gAT TCC TTg Cg-3󸀠) and wild-
type gene (oIMR1273; 5󸀠-AACCTTCAg gATCTgTgATCC-
3󸀠, oIMR1274; 5󸀠-gTg gCT gTT gCC TTA AgA CC-3󸀠). After
PCR cycles, sampleswere loaded onto 2% agarose gels and the
mutated band (209 bp) as well as the wild-type band (178 bp)
was monitored.
Total RNA was extracted from tissues according to
the phenol-chloroform extraction protocol in Tri Reagent
(Molecular Research Center, Inc., Cincinnati, USA) [26].
cDNA was created by a reverse transcription of 2𝜇g of
total RNA using Superscript II Transcriptase from Invitrogen
(Life Technologies, Carlsbad, USA) according to the man-
ufacturer’s protocol. Real-time RT-PCR was performed on
Applied Biosystems’ 7000 Sequence Detection System (Life
Technologies, Carlsbad). Twenty-time diluted cDNA samples
and 0.3 𝜇M forward and reverse primers (Microsynth AG,
Balgach, Switzerland) in a final 10 𝜇L volume were reacted
in the following PCR cycle conditions: 10 minutes at 95∘C
followed by 40 cycles of 15 seconds at 95∘C and 1 minute
at 60∘C. Each sample was analyzed in duplicate using the
DeltaDeltaCtmethod [27].𝛽2microglobulin (𝛽2M)was used
as a housekeeping gene to normalize the expression of each
gene.
2.7. Statistics. All data are shown in mean ± standard error
of the mean (SEM). Two groups were compared by Student
t-test. Four groups were compared by one-way analysis of
variance (ANOVA) and once it reached the significance
(𝐹 < 0.05), a post hoc test (Tukey Kramer HSD test) was
performed. The statistical analyses were performed by use of
the JMP software (SAS Institute Inc., Cary).
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Figure 6: Effect of 4-week CCl
4
treatment on hepatic gene expression and fibrosis in wild-type andMHCIIΔ/Δ mice. Open bars represent oil-
treated wild-type (WT-oil, 𝑛 = 7), closed bars CCl
4
-treated wild-type (WT-CCl
4
, 𝑛 = 11), gray bars oil-treated MHCIIΔ/Δ mice (MHCIIΔ/Δ-
oil, 𝑛 = 5), semiclosed bars CCl
4
-treated MHCIIΔ/Δ mice (MHCIIΔ/Δ-CCl
4
, 𝑛 = 9). Data are presented as mean ± SEM. (a) MHC II gene
expression. (b) Gene expression related to fibrosis formation. (c) Gene expression related to inflammation. (d) No difference in fibrosis
(%) between groups treated by CCl
4
. The percentage was determined based on the sirius red staining (5 pictures/mice, WT-CCl
4
: 𝑛 = 5,
MHCIIΔ/Δ-CCl
4
: 𝑛 = 8). a,b,c𝑃 < 0.05, ANOVA and Tukey Kramer HSD test. Different letters indicate the significant difference between
groups.
3. Results
3.1. Validation of the Mouse Model. The MHCIIΔ/Δ mice
were originally created by the laboratory of Dr. Christophe
Benoist (Institut de Ge´ne´tique et de Biologie Mole´culaire
et Cellulaire, Illkirch, France). These mice lack the major
genes of MHC II pathway and present very low counts
of CD4+ T lymphocytes in the thymus and spleen [19].
The detailed genetic modification and their phenotype have
been published [19]. These mice have been backcrossed with
C57B6/J strain at Jackson laboratory. After purchasing the
mice from Jackson laboratory, we crossed themwith C57B6/J
mice to obtain control wild-type animals. In this model, the
PCR for detecting the knockout allele showed a clear band at
209 bp.The quantitative PCR analysis showed no or very low
expression of the genes of the MHC II pathway (Figure 1).
3.2. Effect of High-Fat Diet on Inflammatory Status in
MHCIIΔ/Δ Mice. Both wild-type and MHCIIΔ/Δ mice sim-
ilarly gained body weight after 4-month high-fat diet
(Figure 2). Liver weight was also similar in both groups.
Plasma glucose and insulin concentrations were comparable
between groups. As expected, both groups had similar glu-
cose tolerance after the long-term high-fat diet. The liver TG
content was also comparable between groups (Figure 3). Oil
red O staining confirmed this result (Figure 4). Plasma ALT
andAST levels were equally high after the high-fat diet in two
groups (Figure 3), suggesting similar liver functions after the
high-fat diet.
To study the inflammatory status of the liver after the
long-term high-fat diet feeding, we have performed H&E
staining and F4/80 for macrophages staining. We observed
positive markers of F4/80 and similar lipid droplet morphol-
ogy in both groups (Figure 4).The expression of genes related
to inflammation such as IL-6, TNF-𝛼, PAI-1, and F4/80 was
not different between groups (Figure 3). The mRNA levels
of fibrosis markers such as collagen type 1𝛼1 (Col-1𝛼1) and
matrix metalloproteinase-14 (MMP-14) were also compara-
ble. We also measured active PAI-1 concentration in the
plasma (Figure 3). Again no difference was observed between
wild-type and MHCIIΔ/Δ mice. All together, blocking the
MHC II pathway did not affect the hepatic inflammation
induced by the high-fat diet in mice.
3.3. Effect of CCl
4
Injection on the Formation of Hepatic
Fibrosis inMHCIIΔ/ΔMice. Wenext studied the development
of hepatic fibrosis. To this end, we treated wild-type and
MHCIIΔ/Δ mice with CCl
4
during 4 weeks. The treatment
resulted in a significant decrease of glycemia and a significant
increase of ALT and AST in both groups (Figure 5). No
difference in liver weight was observed. The CCl
4
injections
also highly induced the expression of MHC II genes in
wild-type mice, while MHCIIΔ/Δ mice had no induction
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Figure 7: Effect of 4-week CCl
4
treatment on liver histology in wild-type and MHCIIΔ/Δ mice. (a) Sirius red staining for collagen. The red
staining represents fibrotic area. (b) Hematoxylin and eosin (H&E) staining.
of these genes, as expected (Figure 6). Genes related to the
fibrosis formation such asCol-1𝛼1, Col-3𝛼1, and transforming
growth factor-𝛽 (TGF-𝛽) significantly increased in both
groups after the CCl
4
injections compared to the oil-injected
groups. The genes such as MMP-14 and tissue inhibitor of
metalloproteinase-2 (TIMP-2) were also highly induced after
CCL
4
treatment in wild-type mice: however, the induction
was somewhat blunted in MHCIIΔ/Δ mice.
The liver histology was analyzed using sirius red staining
for fibrosis formation. No positive staining was detected in
oil-treated groups. The level of positive staining in CCl
4
-
treated livers was quantified using Photoshop. We detected
a comparable level of fibrosis between groups treated by CCl
4
(Figures 6 and 7). H&E staining also showed inflammatory
signs in the liver treated by CCl
4
(Figure 7). Again, no
remarkable difference was observed between wild-type and
MHCIIΔ/Δ mice. The staining by F4/80 showed a remarkable
infiltration of macrophages in the livers of mice treated by
CCl
4
, but, again, no difference was observed between wild-
type and MHCIIΔ/Δ mice (Figure 8). We further stained stel-
late cells by GFAP. Interestingly we detected only one positive
staining out of 13 in wild-type mice while we found 7 positive
stainings out of 9 samples in MHCIIΔ/Δ mice (Figure 9).
4. Discussion
The present study demonstrated that the MHC II pathway is
not implicated in the development of hepatitis when induced
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4
treatment on macrophage staining in wild-type and MHCIIΔ/Δ mice. Macrophage staining (F4/80) showed
a strong inflammation in both groups treated by CCl
4
.
by a long-termhigh-fat diet.Wehad taken the approach of the
high-fat diet to mimic our obesogenic lifestyle that is known
to contribute to the nonalcoholic steatohepatitis (NASH). It is
also strongly supported that feeding laboratory animals with
high-caloric diets such as a high-fat diet can induce NASH
[28–30]. As proposed in the pathophysiology of NASH, the
“two-hit theory” could also explain the progression of hepatic
steatosis to NASH in our experimental model. The first hit is
an infiltration of fat into the hepatocytes (hepatic steatosis)
and the second hit is characterized by an infiltration of
immune cells such as monocytes and lymphocytes because
of abnormal oxidative stress [31, 32]. Our mice having
undergone a 4-month high-fat diet presented a high amount
of fat content in the liver in both groups (first hit). Extensive
high-fat diet feeding then resulted in a comparable increase
of hepatic inflammation/damage in two groups, judged by
macrophage infiltration (second hit). These data suggest that
the long-term high-fat diet induced both hepatic steatosis
and NASH; however, blocking the MHC II pathway had no
influence on the development of hepatic steatosis and NASH
in these mice.
Our long-term high-fat diet also increased the level of
ALT and AST in both groups compared to the normal
range of ALT and AST generally observed in chow-fed
mice (15–80U/L and 40–120U/L, respectively, in our labo-
ratory measurements). This result strongly suggests that the
modification inMHC II gene expression affected neither ALT
nor AST levels, consistent to their comparable liver histology
between groups. It has been, however, suggested that some
alleles in MHC II pathway were associated with a severity of
NAFLD and ALT, but not AST levels, in a Turkish population
[33]. In this study, the investigators could not assess a
presence of NASH in the population. To our knowledge, this
study is the only report suggesting an association between the
HLA allele and NAFLD in general population. Many other
studies have shown a connection between the HLA allele and
plasma ALT or NASH severity in hepatitis C patients or in
patients with a drug-induced liver injury [3, 6, 8, 9, 34, 35].
Therefore, MHC II pathway might have a bigger importance
to the development of NASH caused by viral infections or
drugs than by diet-induced NAFLD.
Secondly, we focused on the chemically induced fibrosis
inmice lacking all conventionalMHC II genes. Asmentioned
before, some HLA alleles are associated with an increased
susceptibility to develop a drug-induced liver injury. The
CCl
4
treatment strikingly increased the plasma level of ALT,
AST, and the degree of hepatic fibrosis in both genotypes.The
genes of MHC II pathway were also highly induced by CCl
4
treatment in wild-type mice, indicating the upregulation of
the pathway upon the treatment. Despite the lack of the
upregulation of the pathway, the MHCIIΔ/Δ mice equally
developed a hepatic fibrosis. These data strongly indicate
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Figure 9: Effect of 4-week CCl
4
treatment on GFAP staining in wild-type and MHCIIΔ/Δ mice. Glial fibrillary acidic protein (GFAP; white
arrows) was stained in red. Increased positive staining was observed in CCl
4
-treated MHCIIΔ/Δ mice. Blue: DAPI staining.
that theMHC II pathway is not required for the development
of hepatic fibrosis, at least in the mouse model of CCl
4
-
induced hepatic fibrosis.
Although the major genes implicated in the formation of
fibrosis, namely, Col-1𝛼1, Col-3𝛼1, and TGF-𝛽 were similarly
upregulated in the groups of mice treated by CCl
4
, the
induction of some genes such as TIMP-2 andMMP-14 tended
to be lower in theMHCIIΔ/Δ mice compared to the wild-type
mice. TIMP-2 expression has been observed during the early
stages of fibrogenesis induced by a porcine serum [36]. We
thought that the deletion ofMHCII genesmight have affected
the progression of fibrosis at an earlier time point. In our
study, we had tested different periods of injection of CCl
4
(2-,
4-, 6-, and 8-week treatment) in these mice. In any condition
tested, we did not observe a significant difference in the gene
expression related to the fibrosis formation (data not shown).
We also confirmed these results by liver histology. This again
supports the idea that the MHC II pathway is not interfering
with the development of hepatic fibrosis induced by CCl
4
.
Although histological data suggested that there was no
difference in the severity of the fibrosis between groups
treated by CCl
4
, we found a profound increase in the hepatic
stellate cells (HSC) staining only in the group of MHCIIΔ/Δ
mice treated by CCl
4
. HSC are nonparenchymal cells in
the liver and are known to play an important role in
fibrosis and tissue repairing [37]. Upon the quiescent HSC
activation, they are converted into myofibroblasts, which are
responsible for the production of extracellular matrices [38].
The importance of the HSC activation in fibrogenesis was
recently reported by Puche et al. [39]. They have elegantly
created a transgenic mouse model whose proliferating HSC
were selectively killed. By use of the model, Puche et al.
demonstrated that these mice had reduced fibrotic area upon
CCl
4
treatment compared to their genetically controlled
counterparts. This signifies the important role of HSC in the
development of hepatic fibrosis.
In our study, despite the hyperactivation of HSC in
MHCIIΔ/Δ mice, the fibrosis formation was strictly compa-
rable between groups. We do not know the exact cause and
effect of this HSC induction in MHCIIΔ/Δ mice treated by
CCl
4
. We have observed that the expression of the genes of
the MHC II pathway was very high in HSC fraction when
we separated different cellular types in the liver (hepato-
cytes, HSC, Kupffer cells, and endothelial cells) (unpublished
data). This suggests that the HSC could play an important
role for the MHC II reaction. We do not know, however,
whether the absence of the pathway inMHCIIΔ/Δmicemight
have affected the HSC proliferation upon CCl
4
stimulation.
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On the other hand, the activation of HSC during the develop-
ment of fibrosis is suggested to be transient [40]. We did not
identify when HSC started to be activated inMHCIIΔ/Δ mice
during the CCl
4
treatment. Whether this hyperactivation of
HSC has compensated the lack of the MHC II pathway and
contributed to the fibrosis formation needs to be further
addressed.
The present study clearly demonstrated that the lack of
MHC II pathway affected neither NASH induced by high-
fat diet nor fibrosis induced by CCl
4
in mice. Despite a large
number of publications implying the association between the
alleles in the MHC II pathway and drug-induced liver injury
and hepatitis C in humans, this study clearly indicated that
the MHC II pathway is not required in the development of
NASH and fibrosis at least in mice.
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